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Purpose/Objective: Meningiomas comprise one third of the the 
primary brain tumor cases and occupy the second place (up to 20%) 
after gliomas concerning the extension among the tumors of the CNS. 
Surgical resection is regarded as choice method for meningioma 
treatment. However, in cases of complex localization and in case of 
placement near vital neurovascular structures, and also in case of 
partial resection or extended tumor growth, usage of stereotactic 
radiosurgery allows preventing of possible complications and reaching 
of radiosurgical control over the tumor. 
Materials and Methods: 63 patients with meningiomas underwent 
treatment at MC'Cyber Clinic of Spizhenko'. Acquired results of 42 
patients were analyzed. Among them 21 patient previously underwent 
surgery (1-3 operations), and 24 patients did not previously undergo 
surgery. Tumor volume was defined between 1.6 ml to 86.6 ml (on 
average 26.8ml). All the patients underwent course of stereotactic 
radiosurgery with the use of CyberKnife system for 1-5 fractions (on 
average 4.45) depending on the tumor volume. Radiation dose ranged 
from 1500 to 2800 cGy. All patients underwent standard assessments, 
as CT, MRI, and also magnetic-resonance imaging in regime of 
diffusion-weighed images (DWI) with definition of actual diffusion 
coefficient – ADC (Apparent Diffusion Coefficient). DWI and ADC 
implementation before and after radiosurgical treatment allowed not 
only qualitative, but also quantitative interpretation conducting of 
acquired results and objective assessment of tumor tissue reaction 
onto the radiation exposure  
Results: Radiological results assessment of radiosurgical treatment 
was conducted in 3, 6, 12 months. In majority of the cases there was 
clinical response evidenced. For the time of patients’ observation for 
3-30 months (on average 17.36 months) tumor volume decreased in 25 
patients (56.2%), 16 patients (35.6%) had the tumor unchanged 
(stabilization) and 1 patient (2.2%) had tumor growth. ADC coefficient 
increase was determined in all patients with tumor volume decrease 
and also in some patients with stable mass lesions’ sizes, and it 
significantly decreased in those patients who had extended 
meningioma growth. Thus, diffusion coefficient increase is evidenced 
in 27 (64.3%) of the patients. Hereinafter the conditions of those 
patients continued improving. At the same time, according to the 
literature data, without taking into account the ADC of MRI diffusion-
weighed images, decrease of tumor (meningioma) after radiosurgery 
was observed only in 18%, and stabilization of the process was seen in 
74% of the patients. ADC diffusion parameters in our patients with 
meningiomas before the start of treatment comprised 0.6-0.96 
mm2/s. After radiosurgical treatment diffusion coefficient equaled 
0.64-1.64 mm2/s. 
Conclusions: Stereotactic radiosurgery with the use of CyberKnife is 
effective treatment method for brain meningiomas. Objective 
assessment of treatment results is possible only by means of standard 
radiological methods (CT, MRI), supplemented with special MRI modes 
(DWI) and ADC determination. 
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Purpose/Objective: Radiation necrosis (RN) of the brain is an 
important problem for the patient with malignant astrocytoma, 
especially treated with high-dose RT. Individualized radiation dose 
delivery according to radiosensitivity may reduce the incidence of RN 
while keeping enough anti-tumor effect. And anti-tumor effect of 
irradiation was closely related to anti-tumor immune response of the 
host. The purpose of this study is to evaluate whether some 
parameters, which speculate the host's immune strength, could 
predicted the occurrence of RN at initial treatment. 
Materials and Methods: Between 2006 and 2010, 64 patients with 
malignant astrocytoma were enrolled. All patients were treated with 
RT and concurrent temozolomide (TMZ) followed by adjuvant TMZ. 
Thirty-three patients received conventional RT and the other 31 
received hypofractionated high-dose IMRT. In the IMRT group, three-
layered PTVs were contoured (PTV-1: enhanced lesion with 5mm 
margin, PTV-2: 15mm surrounding the PTV-1, PTV-3: FLAIR-high area) 
and different doses (68Gy for PTV-1, 40Gy for PTV2 and 32Gy for PTV-
3) were delivered by 8 fractions. To estimate the immune strength of 
the patients, we used tumor-infiltrating lymphocytes (CD4+ helper T 
cells, CD8+ cytotoxic Tcells and FoxP3+ regulatory T cells (Treg) which 
suppresses the cytotoxic effect of CD8+ T cells) at first surgery, 
cerebrospinal fluid cells and proteins a week after first surgery. After 
treatment, MRI was performed with an interval of one or two months. 
We estimated the prognostic effect of these immunobiological 
parameters on overall survival (OS), progression-free survival(PFS) and 
RN-free survival (RNFS). 
Results: High-dose hypofractionated IMRT induced RN more frequently 
than conventional RT (relative risk (RR) 3.44, p=0.0067) and tumor-
infiltrating CD8+ T cells was also independent risk factor of RN (RR 
3.10,p=0.0262). On the other hand, the infiltration of FoxP3+ Treg 
indicated lower risk of RN but not statistically significant. One-year 
RNFS for CD8 infiltration without FoxP3 and FoxP3 infiltration without 
CD8 were 50% and100%. Two-year RNFS were 0% and 86%, respectively 
(p=0.0013).Tumor-infiltrating lymphocytes was not related to OS and 
PFS in the entire analysis. In the subgroup analysis of IMRT, the 
infiltration of CD8+ cells was higher risk factor of RN (RR 3.88, 
p=0.0041). In the conventional RT group, the infiltration of CD8+ 




Conclusions: Tumor-infiltrating CD8+ T cells was the prognostic factor 
of RN after RT, especially high-dose RT, but was not related to OS. 
The analysis of tumor-infiltrating lymphocytes might be useful to 
prevent the occurrence of RN. 
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Purpose/Objective: To analyze the treatment outcomes and 
prognostic factors in patients with brain metastases (BM) from 
undiagnosed primary cancer (BM-UDP). 
Materials and Methods: Between January 2010 and October 2012, 
patients with brain metastases referred for palliative radiotherapy 
were enrolled for this study. BM-UDP patients underwent complete 
systemic survey for the origin of the cancer before the treatment 
began. All patients were treated with long-term palliative intent 
including whole brain radiotherapy (WBRT) and systemic therapies 
tailored for their primary origin. Patients were followed up until their 
death and overall survival (OS) were calculated from the day of BM 
diagnosis. Another group of patients with BM from diagnosed primary 
(BM-DP) who were treated in the same period of time were used for 
survival comparison. Potential prognosticators for OS in BM-UDP were 
analyzed. 
Results: Total 79 BM patients were treated and enrolled during this 
period, 37 were BM-UDP and 42 were BM-DP. There were no survival 
difference between BM-UDP and BM-DP patients compared by 
univariate analysis (p = 0.298). In BM-UDP patients, the median age 
was 61 years-old, 22 were male and 15 were female. The most 
common primary site was the lung (30/37). Median OS for these 
patients were 8.03 months. Multivariate analysis revealed that age, 
gender, extracranial metastases, number of BM lesions, and volume of 
the largest BM lesion were not prognosticators for OS. The only 
significant prognostic factor was performance status before WBRT. 
The median OS were 10.00 months and 2.89 months for patients with 
Karnofsky performance status (KPS) ≥ 70 and KPS < 70, respectively. 
(p = 0.006) 
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Conclusions: Patients with BM-UDP demonstrated comparable survival 
to those with BM-DP. The only prognosticator in our study for BM-UDP 
patients was KPS. Tailored therapeutic strategy with long-term 
palliative intent including WBRT and systemic therapies is reasonable 
for all BM-UDP patients with good performance status.  
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Purpose/Objective: Meningiomas account approximately for 15-20% of 
all primary brain tumours in adults. Neurosurgical resection has been 
considered the first treatment of choice but definitive radiotherapy 
(RT) or postoperative RT for sub-totally resected tumours is an 
integral modality in the treatment of meningiomas. Although short 
term toxicity from RT is uncommon, the potential late RT effects can 
be severe. Radiation treatment planning for Meningiomas can be 
challenging. The ultimate goal is to spare the critical structures while 
delivering the prescribed treatment dose to the target volume. A 
planning comparison was undertaken of both planning techniques to 
establish if there was a dosimetric advantage of VMAT compared with 
3D-CRT with particular reference to dose to PTV coverage and dose to 
normal brain. 
Materials and Methods: 12 patients (8 females, 4 males) with 
Meningioma have been treated over the past 18 months. 60% of 
patients received RT following surgical resection. All patients were 
planned with 3D-CRT and VMAT, optimising dose to tumour. Total dose 
was 50.4Gy in 28 fractions. The GTV was delineated on CT/MRI co-
registered images. A CTV-PTV margin of 0.7cm was added. The 
median treatment volume was 111cc (56-190). Analytical Anisotropic 
Algorithm (AAA) was used to calculate the plans. 
Results: For the PTV, the comparison parameters include mean dose 
and conformation number. Calculation of the conformation number 
(CN) took into account the coverage of the PTV and volume of healthy 
tissue receiving dose above the prescribed dose. 1 is the ideal value. 
Mean PTV dose: 3D-CRT 50.7Gy (range 41.3Gy-54.7Gy) ±4.2 (SD),  
VMAT 50.6Gy (range 50.3Gy-53.9Gy) ±1.3 (SD). 
CN for 3DCRT = 0.446 (range 0.32-0.550) 
VMAT = 0.823 (range 0.70-0.90).  
Absolute improvement in CN in VMAT plans over 3D-CRT was 0.352 
(range 0.206-0.508). 
Normal brain doses :V45 3D-CRT 5.93% (range 3.3%-14.3%), VMAT 
1.41% (range 0.8%-3.8%).  
V10 3D-CRT 38.5% ( range 24.2%-46.9%), VMAT 33.7% (range 24.7%-
55.9%) 
Conclusions: 3D-CRT and VMAT plans achieved equivalent PTV 
coverage. However, VMAT plans achieved superior homogeneity. The 
CN varies considerably leading us to conclude that the PTV coverage 
in the 3D-CRT plans is sub optimal. Although the CN for the VMAT is 
not ideal, it is substantially better. V 45Gy is better in the VMAT plans 
however, V10 is comparable.  
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Purpose/Objective: The aim of the work was to evaluate changes in 
NAA,Cho, lactate and lipid peaks after radiotherapy of partially 
operated gliomas as compared with 1H-MRS data gained before 
radiotherapy. Proton magnetic resonance spectroscopy gives 
information related to cell membrane proliferation, neuronal function 
metabolism and necrotic transformation of brain or tumor tissues. 
Spectroscopy added to MRI helps in tissue characterization of 
intracranial lesions, which could be of help in diagnostic of local brain 
disease. MRS could be helpful in the differentiation of high grade from 
low grade brain tumors, and perhaps in separating recurrence from 
radiation injury. Reduction in the resonance intensity of NAA (N-
acetylaspartate) in the white matter of the brain in MR spectroscopy 
investigations reflects changes in metabolism or axonal density. Active 
demyelization produces changes in the resonance from choline. 
Lactate increases with inflammation due to anaerobic metabolism of 
inflammatory cells,associated mitochondrial dysfunction or occlusion 
of micro vessels. In normal brain NAA produces the highest peak in 
MRS examination. Gliomas malignancy tends to increase with decrease 
in NAA levels. Cho increases at a higher rate with more rapid 
development of neoplasm. Cho is one of the components of membrane 
metabolites and reflects membrane turnover. The presence or 
elevation of lactate and lipid has been attributed to rapid tumor 
growth and necrosis and indicates high tumor grade. Cho peak is 
identified as a marker of tumor cell proliferation. 
Materials and Methods: 52 patients with gliomas with partial 
resection of tumors were subjected to MRI with 1H-MRS examination 
before and after radiotherapy (60 Gy, 2 Gy/day). NAA, Cho, lactate 
and lipid peaks before irradiations were chosen as basic values. 
Results: Changes in peak intensity after radiotherapy depend on the 
malignancy grade of the tumor. Lactate and lipid levels were reduced 
after radiotherapy. NAA level increased. Cho changes were 
unpredictable especially for tumors with high grade of malignancy. 
Changes in NAA, Cho, lipid and lactate peaks could help in evaluation 
of radiotherapy effectiveness and in detection of early recurrence in 
gliomas. 
Conclusions: Changes in peaks intensity after irradiation could be of 
prognostic values. 
   
EP-1005   
Bone marrow invasion by Hodgkinís disease: what is the role of 
radiotherapy in treatment strategy? 
M. Girshovich1, S.V. Kanaev1, S.N. Novikov1, L.A. Jukova1, M.L. 
Gershanovich2 
1N.N. Petrov Institute Oncology, Radiation Oncolgy & Nuclear 
Medicine, Saint-Petersburg, Russian Federation  
2N.N. Petrov Institute Oncology, Chemotherapy, Saint-Petersburg, 
Russian Federation  
 
Purpose/Objective: To determine role of irradiation in the treatment 
of patients with advanced Hodgkin’s disease (HD) and bone marrow 
(BM) involvement.  
Materials and Methods: 632 patients (pts) with advanced HD were 
included in this retrospective analysis. In all cases diagnosis of HD 
were confirmed by histology. Extranodal lesions diagnosed in 206 of 
632 pts. Since 1992 whole body BM scintigraphy with 99m??-
nanocolloids visualization is a part of routine staging. All cases of BM 
lesions revealed by scintigraphy were verified by biopsy, additional 
instrumental survey and by follow-up. All pts receive 4-8 cycles of 
chemotherapy with MOPP-ABVor ABVD or BEACOPP. In 45 pts 
visualized BM lesions were irradiated within 20Gy-50Gy (average dose 
38.1Gy). BM lesions were outside radiation fields in another 30 cases. 
Results: In 206 pts with extranodal disease BM invasion revealed in 75 
(36%) cases: 51 pts had one-two BM lesions and another 21 – multifocal 
BM involvement. Overall (OS) and disease free (DFS) 10 year survival 
in pts with BM invasion (49% and 45%) were significantly (p=0,026) 
lower than in other pts with extranodal HD (62% and 65%). In pts with 
only BM involvement and those with BM and other extranodal invasion 
OS and DFS were comparable: 50% versus 47.5% and 48.5 versus 41%. 
On the contrary, OS was significantly different (p=0.014) in pts with 1-
2 BM lesions (57%) and multifocal BM disease (26.5%). Irradiation of BM 
lesions significantly improve 10 year OS (p=0.00005) and DFS (p=0.006) 
in pts with HD: from 16% to 68% and from 23% to 58.5% 
correspondingly. It is especially important that this differences is 
preserved for pts with 1-2 BM foci: 10 year OS and DFS in cases of 
irradiated BM lesions are 72.7% and 57.5% versus 13.5% and 25% - in 
non irradiated BM lesions (p=0.0006 and p=0.054).  
Conclusions:  
1. In pts with advanced HD and BM involvement irradiation of 
visualized BM lesions significantly improve 10 year OS and DFS. 
2. Visualization of BM lesions is of crucial importance for radiotherapy 
planning.  
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Purpose/Objective: MRIs provide us sufficient information regarding 
the tumor bulk, but a little for the infiltrating tumor cells. For the 
precise planning of the irradiation for infiltrating tumors such as 
gliomas, more biological imagings were required to delineate the 
target, and Methinoine(Met)-PET may be one of the candidates. In this 
study, we evaluated the correlations between Met-uptake before 
irradiation, delivered dose and control of the lesions to elucidate the 
optimal dose to control lesions owing to the Met-uptakes. 
